Back to results
US 2023/0068783 A1Published application
Agents that interfere with il-1beta receptor signalling
AssigneeTavotek Biotherapeutics (Hong Kong) Limited
InventorsDi ZHANG, Susan TAM, Minseon CHO, Lihua SHI, Man-Cheong FUNG
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to antibodies that specifically bind and neutralize interleukin-1β (IL-1β), and to the use of such antibodies for the therapeutic treatment of IL-1β-mediated diseases and disorders.
Claims38
An isolated antibody or an antigen-binding fragment thereof that specifically binds to IL-1β and neutralizes, inhibits, blocks, abroqates reduces, or interferes with an activity of IL-1β.
(canceled)
(canceled)
(canceled)
(canceled)
35-37. (canceled)
40-44. (canceled)
Dependencies are inferred from the claim text.